non-peptidic

CGS 27023A is a non-peptidic, potent, and orally active stromelysin inhibitor.

Aclacinomycin A (Aclarubicin) hydrochloride is a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II.

AS057278 (3-Methylpyrazole-5-carboxylic acid) is an D-amino acid oxidase (DAAO) inhibitor.

RP-23618 is a non-peptidic antagonist of RANTES.

RXFP3/4 agonist 2 is a potent non-peptidic bis-RXFP3/4 agonist that induces the interaction between RXFP3 and β-arrestin-2, and can be used to study diseases caused by metabolic abnormalities.

HIV protease-IN-1 (compound 1·succinate), a potent non-peptidic inhibitor of HIV protease, is utilized for AIDS research [1].

Bag-1 is a novel potent, non-peptidic bombesin receptor subtype-3 (BRS-3) agonist.

CypD-IN-29 is a non-peptidic inhibitor of cyclophilin D as a neuroprotective agent in Aβ-induced mitochondrial dysfunction.

Ensitrelvir (S-217622) fumarate is a novel orally active inhibitor, targeting the SARS-CoV-2 3CL protease (IC50 = 13 nM). It demonstrates non-covalent and non-peptidic characteristics. This compound represents a pioneering advancement in the development of effective antiviral agents against the SARS-CoV-2 virus.

Bag-2 is a Novel potent, non-peptidic bombesin receptor subtype-3 (BRS-3) agonist.

THX-B, a potent non-peptidic antagonist of the neurotrophin receptor p75 (p75 NTR), is utilized in the study of diabetic kidney disease, neurodegenerative, and inflammatory disorders [1] [2] [3].

Tanomastat is an orally bioavailable and non-peptidic biphenyl matrix metalloproteinases inhibitor. For MMP-2, MMP-3, MMP-9, MMP-13 the Ki values are 11, 143, 301, and 1470 nM respectively.

PF-184563 is an effective and selective non-peptidic V1a receptor antagonist.

Y2-Antagonist-2 is a novel, selective, soluble non-peptidic NPY Y2 receptor antagonist with enhanced CNS exposure.

HA14-1, a Bcl-2/Bcl-XL antagonist, is a non-peptidic ligand of a Bcl-2 surface pocket (IC50: ~9 μM).

Cgs 26303 is a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation.

LY2811376, an orally available non-peptidic β-secretase(BACE1) inhibitor (IC50: 239-249 nM), can decrease Aβ secretion (EC50: 300 nM). It has 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including pepsin, cathepsin D, or renin.